The increase resulted primarily from higher compensation costs and travel expenses. General and administrative General and administrative expenses increased by $314,606, or 19.5%, to $1,931,578 for the three months ended June 30, 2026 from $1,616,972 for the three months ended June 30, 2025.

filing / Aug 14, 2026 / receipt

The increase resulted primarily from higher compensation costs, travel expenses and professional fees. General and administrative General and administrative expenses increased by $374,283, or 11.2%, to $3,713,968 for the six months ended June 30, 2026 from $3,339,685 for the six months ended June 30, 2025.

filing / Aug 14, 2026 / receipt

The Company is a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, with a broad patent-protected portfolio of disruptive, accessible, in-office therapeutic and diagnostic products.

filing / Aug 14, 2026 / receipt

The increase resulted primarily from higher compensation costs, professional fees and travel expenses. General and administrative General and administrative expenses increased by $59,677, or 3.5%, to $1,782,390 for the three months ended March 31, 2026 from $1,722,713 for the three months ended March 31, 2025.

filing / May 8, 2026 / receipt